Liquidia Corporation

NASDAQ:LQDA

Biotechnology

Healthcare
$56.40 +0.34%

+$0.23 today

Market cap
$5.08B
Beta
0.59
P/E (TTM)
271.8
EPS (TTM)
$0.25
52W Low $11.85High $73.22

Volume 1.22M

Average 1.50M

LQDA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Liquidia CorporationNASDAQ: LQDA

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of $17.18M rose 185.4% year over year, ahead of the +34.8% change in trailing-twelve-month research & development. Sequentially, it rose 40.0% from the prior quarter. Over 3 fiscal years it compounded at +26.4% a year.

Context

  • Research & development amounted to 24.8% of revenue in FY2025, down 317.0 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +185.4% holds above the trailing-twelve-month pace of +34.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$17.18M+40.0% QoQ
Last fiscal yearDec 2025
$39.28M-17.9% YoY
LTMJun 2026
$55.75M+34.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+185.4%——
1 year-17.9%——
3-year CAGR+26.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
39.28M USD
Year-over-year change
-17.9%
4-year CAGR
+17.6%

Research & Development vs competitors

How LQDA compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +34.8% is the highest of 4, against a peer median of +6.0%.
  • Research & development amounts to 12.4% of revenue for LQDA, versus a peer median of 75.7%.
LQDA Competitors
Research & Development for LQDA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INSMInsmed IncorporatedLTM Jun 2026$860.85M USD+30.4%+24.7%75.7%
UTHRUnited Therapeutics CorporationLTM Jun 2026$551.5M USD+6.0%+19.4%17.5%
VCREVicore Pharma Holding ABLTM Jun 2026SEK 238.42M SEK+2.0%+16.0%17927.0%
LQDALiquidia CorporationLTM Jun 2026$55.75M USD+34.8%+26.4%12.4%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding LQDA) —+6.0%+19.4%75.7%

Competitors are the stored peer set for LQDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.85M15.94M17.49M14M158.32M
Cost of Revenue3.02M2.86M2.89M5.88M13.24M
Gross Profit9.83M13.08M14.6M8.12M145.08M
Gross Margin76.5%82.1%83.5%58.0%91.6%
Research & Development20.52M19.44M43.24M47.84M39.28M
Selling, General & Admin23.11M32.41M44.74M81.57M157.18M
Operating Expenses43.63M51.85M87.98M129.41M196.45M
Depreciation & Amortization5.61M3.65M2.18M2.2M1.53M
EBITDA(28.21M)(35.03M)(70.05M)(115.71M)(43.22M)
EBITDA Margin-219.4%-219.8%-400.6%-826.7%-27.3%
Operating Income(33.8M)(38.77M)(73.38M)(121.29M)(51.38M)
Operating Margin-263.0%-243.3%-419.6%-866.6%-32.5%
Interest Income33K1.09M3.47M7.65M6.62M
Interest Expense762K2.34M6.27M12.49M24.17M
Other Income / Expenses(782K)(2.25M)(5.12M)(9.1M)(17.55M)
Income Before Tax(34.58M)(41.02M)(78.5M)(130.39M)(68.92M)
Pre-Tax Margin-269.0%-257.4%-448.9%-931.7%-43.5%
Income Tax Expense00000
Net Income(34.58M)(41.02M)(78.5M)(130.39M)(68.92M)
Net Margin-269.0%-257.4%-448.9%-931.7%-43.5%
EPS (Basic)(0.70)(0.67)(1.21)(1.66)(0.80)
EPS (Diluted)(0.70)(0.67)(1.21)(1.66)(0.80)
Weighted Avg Shares49.68M60.96M64.99M78.71M86.06M
Weighted Avg Shares (Diluted)49.68M60.96M64.99M78.71M86.06M

Liquidia Corporation

NASDAQ:LQDA

Intrinsic Alpha fair value

Locked

Current Price

$56.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.